Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Larsen

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Blood|July 1, 2015
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232Michael J Borowitz, Brent L Wood, Meenakshi Devidas, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology GroupJennifer L McNeer, Meenakshi Devidas, Yunfeng Dai, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2020
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131Wanda L Salzer, Michael J Burke, Meenakshi Devidas, et al.
Blood|May 20, 2015
Genome-wide analysis links NFATC2 with asparaginase hypersensitivityChristian A Fernandez, Colton Smith, Wenjian Yang, et al.
Cancer|July 18, 2013
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemiaSteven E Lipshultz, Stuart R Lipsitz, Jeffery L Kutok, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
Haematologica|November 24, 2018
Trypsin-encoding <i>PRSS1-PRSS2</i> variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group reportBenjamin O Wolthers, Thomas L Frandsen, Chirag J Patel, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Blood|July 1, 2015
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232Michael J Borowitz, Brent L Wood, Meenakshi Devidas, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2019
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology GroupJennifer L McNeer, Meenakshi Devidas, Yunfeng Dai, et al.
Pediatrics|November 21, 2012
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesSteven E Lipshultz, Tracie L Miller, Stuart R Lipsitz, et al.
The Lancet. Oncology|September 21, 2010
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialSteven E Lipshultz, Rebecca E Scully, Stuart R Lipsitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2020
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131Wanda L Salzer, Michael J Burke, Meenakshi Devidas, et al.
Blood|May 20, 2015
Genome-wide analysis links NFATC2 with asparaginase hypersensitivityChristian A Fernandez, Colton Smith, Wenjian Yang, et al.
Cancer|July 18, 2013
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemiaSteven E Lipshultz, Stuart R Lipsitz, Jeffery L Kutok, et al.
Blood Advances|January 26, 2021
Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemiaAnjali S Advani, Eric Larsen, Kristina Laumann, et al.
Haematologica|November 24, 2018
Trypsin-encoding <i>PRSS1-PRSS2</i> variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group reportBenjamin O Wolthers, Thomas L Frandsen, Chirag J Patel, et al.
Pageof 5